# reload+after+2024-01-20 07:45:29.812678
address1§117, Avenue de Luminy
address2§BP 30191
city§Marseille
zip§13009
country§France
phone§33 4 30 30 30 30
fax§33 4 30 30 30 00
website§https://www.innate-pharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
fullTimeEmployees§191
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Herve  Brailly Ph.D.', 'age': 62, 'title': 'Co-Founder, Interim CEO & Chairman of Executive Board', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Yannis  Morel Ph.D.', 'age': 50, 'title': 'Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 408421, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. François  Romagné Ph.D.', 'age': 59, 'title': 'Founder', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.', 'age': 59, 'title': 'Founder, Senior VP & Chief Scientific Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marc  Bonneville Ph.D.', 'age': 63, 'title': 'Founder', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jean Jacques Fournié Ph.D.', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alessandro  Moretta M.D., Ph.D.', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Frederic  Lombard M.B.A.', 'age': 48, 'title': 'Senior VP & CFO', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Odile  Belzunce', 'age': 43, 'title': 'Vice President of Compliance & Operations', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Henry  Wheeler M.Sc.', 'age': 39, 'title': 'Vice President of Investor Relations & Communication', 'yearBorn': 1984, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§4
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.615
priceToSalesTrailing12Months§4.650224
currency§USD
dateShortInterest§1702598400
forwardEps§0.45
exchange§NMS
quoteType§EQUITY
shortName§Innate Pharma S.A.
longName§Innate Pharma S.A.
firstTradeDateEpochUtc§1571319000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§95b2a86c-03b1-3402-a4e5-5bdc8b44e164
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.54
targetLowPrice§2.76
targetMeanPrice§7.47
targetMedianPrice§8.03
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§3.663
earningsGrowth§-0.747
grossMargins§-0.11241
ebitdaMargins§-0.36706
trailingPegRatio§None
